{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003322","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.352235+00:00","generated_at":"2026-06-28T11:33:22.107706+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Caribou Biosciences appoints Dara Richardson-Heron to board and Ruhi Khan as Chief Business Officer","bullets":["Dara Richardson-Heron, M.D., appointed as Class III director effective Nov 4, 2021, and to Nominating Committee.","Ruhi Khan appointed as Chief Business Officer, bringing 20+ years of biotech business development experience.","Board size increased from six to seven directors to accommodate Richardson-Heron's appointment.","Richardson-Heron receives standard director compensation: $40K/yr cash plus $4K/yr for committee; initial option for 44,000 shares vesting over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003322","json":"https://secwatch.observer/filing/0000950170-21-003322.json","markdown":"https://secwatch.observer/filing/0000950170-21-003322.md","text":"https://secwatch.observer/filing/0000950170-21-003322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021003322/0000950170-21-003322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021003322/crbu-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:33:22.107706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d0f2922c2","claim":"Dara Richardson-Heron was appointed as Class III Director at Caribou Biosciences, Inc..","evidence_excerpt":"On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021003322/0000950170-21-003322-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}